IRC
SRPT icon

Investors Research Corp’s Sarepta Therapeutics SRPT Stock Holding History

Investors Research Corp’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-53
Closed -$5K – 1119
2020
Q1 		$5K Hold
53
– – ﹤0.01% 896
2019
Q4 		$7K Hold
53
– – ﹤0.01% 904
2019
Q3 		$4K Buy
+53
New +$6.26K ﹤0.01% 972

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Investors Research Corp's SRPT Position: Q2 2020 in Review

Investors Research Corp sold out of Sarepta Therapeutics (SRPT) in Q2 2020, closing a stake of 53 shares — an estimated $5K sold.

Investors Research Corp first reported a position in SRPT in Q3 2019 and held it in 3 quarters. The position peaked at $7K in Q4 2019. 408 funds tracked by Wall St. Rank hold SRPT as of Q2 2020.

  • Investors Research Corp reported no remaining Sarepta Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Investors Research Corp sold 53 Sarepta Therapeutics shares in Q2 2020, an estimated $5K.
  • Investors Research Corp first reported a position in Sarepta Therapeutics in Q3 2019 and held it in 3 quarters.
  • Investors Research Corp's Sarepta Therapeutics position peaked at $7K in Q4 2019.
  • 408 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2020.

Based on Investors Research Corp's 13F filing for Q2 2020, filed 21 Jul 2020.